Bob Atwill is a Principal of Eaton Square and has over 30-years experience in the global pharmaceutical, biotechnology, cellular therapies, COVID-19, CAR-T IO, IT, medical device, diagnostic, healthcare services, life science and consultancy sectors. He has been a CEO for over 17 years and a Senior Executive and Corporate Officer in NYSE, LSE & ASX organisations since 1997.
He is currently Head of Asia-Pacific Region for Humanigen, Inc. the NASDAQ-listed clinical stage biopharmaceutical company, developing an immunology and immuno-oncology portfolio of monoclonal antibodies for COVID-19, CAR-T therapy and acute GvHD.
Bob has grown two Strategy and Business Development consultancies and led a diverse range of M&A, Capital Raising and Corporate activities. He has also been SVP New Business & Collaborations for Benitec Biopharma the NASDAQ/ASX-listed gene therapy company, CEO of Cytomatrix (now Nohla Therapeutics based in Seattle), Managing Director of Fitgenes Australia Ltd and was a Group Executive and Regenerative Medicine Division CEO for Allied Healthcare Group (now Admedus).
He has consulted in strategy and commercialisation for ASX-listed Mesoblast across its portfolio of Mesenchymal Precursor Cells. Bob was a Director for Cyto Therapeutics Pty Ltd, the Australian subsidiary of San Diego based International Stem Cell Corporation (ISCO) focused on phase I &II trials in Parkinson’s disease and traumatic brain injury. He was also the CEO & MD of Clinical Cell Culture, an ASX-listed stem cell therapeutic and device company (now Avita Medical), Sales & Marketing Director of the LSE-listed Corin Group Plc and European Managing Director of the NYSE-listed Sun Healthcare Group Inc.
Bob has a BSc (Hons) in biochemistry from the University of Bristol and an MBA from Ashridge Management College (Hult) in the UK. He has also participated in Executive/President programs in the United States at Yale and UCLA. Bob is a member of the Institute of Directors and Chartered Institute of Marketing.